1
|
de Gaetano M, Tighe C, Gahan K, Zanetti A, Chen J, Newson J, Cacace A, Marai M, Gaffney A, Brennan E, Kantharidis P, Cooper ME, Leroy X, Perretti M, Gilroy D, Godson C, Guiry PJ. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A 4 Mimetics (QNX-sLXms). J Med Chem 2021; 64:9193-9216. [PMID: 34138563 PMCID: PMC8279484 DOI: 10.1021/acs.jmedchem.1c00403] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
![]()
Failure to resolve
inflammation underlies many prevalent pathologies.
Recent insights have identified lipid mediators, typified by lipoxins
(LXs), as drivers of inflammation resolution, suggesting potential
therapeutic benefit. We report the asymmetric preparation of novel
quinoxaline-containing synthetic-LXA4-mimetics (QNX-sLXms).
Eight novel compounds were screened for their impact on inflammatory
responses. Structure–activity relationship (SAR) studies showed
that (R)-6 (also referred to as AT-02-CT)
was the most efficacious and potent anti-inflammatory compound of
those tested. (R)-6 significantly attenuated
lipopolysaccharide (LPS)- and tumor-necrosis-factor-α (TNF-α)-induced
NF-κB activity in monocytes and vascular smooth muscle cells.
The molecular target of (R)-6 was investigated.
(R)-6 activated the endogenous LX receptor
formyl peptide receptor 2 (ALX/FPR2). The anti-inflammatory properties
of (R)-6 were further investigated in vivo in murine models of acute inflammation. Consistent
with in vitro observations, (R)-6 attenuated inflammatory responses. These results support
the therapeutic potential of the lead QNX-sLXm (R)-6 in the context of novel inflammatory regulators.
Collapse
Affiliation(s)
- Monica de Gaetano
- School of Medicine, Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Catherine Tighe
- Centre for Synthesis and Chemical Biology, School of Chemistry, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Kevin Gahan
- Centre for Synthesis and Chemical Biology, School of Chemistry, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Andrea Zanetti
- Centre for Synthesis and Chemical Biology, School of Chemistry, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Jianmin Chen
- William Harvey Research Institute, Queen Mary University London, London EC1M 6BQ, U.K
| | - Justine Newson
- Centre for Clinical Pharmacology, University College London, London WC1E 6JF, U.K
| | - Antonino Cacace
- School of Medicine, Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Mariam Marai
- School of Medicine, Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Andrew Gaffney
- School of Medicine, Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Eoin Brennan
- School of Medicine, Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Phillip Kantharidis
- Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia
| | - Mark E Cooper
- Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia
| | - Xavier Leroy
- Domain Therapeutics SA, 67400 Strasbourg, Illkirch, France
| | - Mauro Perretti
- William Harvey Research Institute, Queen Mary University London, London EC1M 6BQ, U.K
| | - Derek Gilroy
- Centre for Clinical Pharmacology, University College London, London WC1E 6JF, U.K
| | - Catherine Godson
- School of Medicine, Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| | - Patrick J Guiry
- Centre for Synthesis and Chemical Biology, School of Chemistry, UCD Conway Institute, University College Dublin, Belfield, Dublin D04 N2E5, Ireland
| |
Collapse
|